TrialClinical pharmacology and therapeutics2026

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First-in-Human Studies in Healthy Participants and Patients.

Eleanor A Lisbon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.